#### FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

wasnin	gton,	D.C.	2054

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b)

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average bu	urden								
hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  WILSON JAMES N					2. Issuer Name and Ticker or Trading Symbol  CORCEPT THERAPEUTICS INC [ CORT ]									of Reporting Pers cable) or		10% Owner			
(Last) (First) (Middle) C/O CORCEPT THERAPEUTICS 149 COMMONWEALTH DRIVE				3. Date of Earliest Transaction (Month/Day/Year) 11/11/2008								Office below	r (give titl )	е	Other below	(specify )			
(Street)	PARK C	A State)	94025 (Zip)	on Dori	-	4. If Amendment, Date of Original Filed (Month/Day/Year)  ative Securities Acquired, Disposed of, or Benefic						Lir	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person						
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da			ction	ion 2A. Deemed Execution Date,		3. 4. Securities Acquired (Disposed Of (D) (Instr. 3)		ed (A) or	r 5. Amount of Securities Beneficially Owned Following		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of ndirect Beneficial Ownership						
									Code	v	Amount	(A) or (D)	Price	Reported Transactio (Instr. 3 ar	on(s) nd 4)			(Instr. 4)	
Common Stock 11/11/2				2008	008		A		3,494(	1) A	\$1.45	2,074	,511	]	1	By Trust			
Common	Stock													I bbb UbU I I I '			By Family Partnership		
			Table II								posed o			y Owned		,			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Exercise (Month/Day/Year) ce of ivative		Execution Date, if any		4. Transaction Code (Instr. 8)		n of		6. Date Exercisa Expiration Date (Month/Day/Yea		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisal	ble	Expiration Date	Title	Amount or Number of Shares						
Stock option (right to buy)	\$1.51								(2)		05/18/2017	Common Stock	250,000		250	,000	D		
Warrants	\$2.77								03/25/20	08	03/24/2015	Common	17,652		17,	652	I	By Family	

#### **Explanation of Responses:**

1. Acquired from the issuer pursuant to the Amendment to Registration Rights Agreement dated November 11, 2008 in full satisfaction of cash liquidated damages owed under the Registration Rights Agreement dated as of March 14, 2008. The shares of common stock were valued at \$1.45 per share, the closing market price of the common stock on the NASDAQ Capital Market on November 11, 2008.

### Remarks:

/s/ Joseph K. Belanoff, CEO of

**Corcept Therapeutics** 

11/13/2008

Inocrporated attorney-in-fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>2.</sup> Exercisable with respect to 2.0834% of the total number of Option Shares on the monthly anniversary of 5/18/2007 each month thereafter.